Sponsored Post An interview with Christina Liston, Director of Patient Access at PharmaEssentia It’s no secret in the polycythemia vera (PV) community that the patient journey comes with many challenges, sometimes feeling like a roller coaster ride. It impacts us at a physical, mental, and spiritual level. For many people, the disease comes with a […]
MPN Patient Advocacy Works!
by David Wallace I got my first shot of Pegasys 3 days ago and local doc’s agreement to monitor my counts. It was not without a HARD push on my part as doc was still pushing the benefits of HU (hydroxyurea), while reinforcing the numerous risks with Peg, go figure. For once, I was glad […]
Pregnancy and Childbirth Outcomes in Women with MPNs
A Nationwide population-based study of 342 pregnancies in Sweden Abstract Pregnancy and childbirth in women with myeloproliferative neoplasms (MPN) are reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction. To assess the risks of adverse events in pregnancy in women with MPN, we performed a large population-based study using Swedish health care registers, […]
MPN Awareness Day!
by David Wallace Today we celebrate MPN Awareness Day with our community! We are focused 24/7 on providing valuable resources to patients, caregivers and healthcare providers via our websites PV Reporter and MPN Cancer Connection. MPN Awareness and education is a daily practice rather than a special event. —> For myself personally, I take great […]
Paving the way to improve therapy for MPNs
Megan Bywater & Steven W. Lane, Nature Communications volume 13, Article number: 5025, Published: August 26, 2022 Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in Nature Communications, have identified promising candidates that may synergize with IFNα by targeting stem cell function or feedback loops that mediate […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 37
- Next Page »
